The Potamkin PrizeImmunotherapy of Alzheimer DiseaseNitsch, Roger M. MDAuthor Information From the University of Zurich, Division of Psychiatry Research, Zürich, Switzerland. Supported by grants from the NCCR on Neural Plasticity and Repair, EU-APOPIS, and the Stammbach Foundation. Reprints: Roger M. Nitsch, MD, University of Zurich, Division of Psychiatry Research, August Forel Strasse 1, 8008 Zürich, Switzerland (e-mail: firstname.lastname@example.org). Alzheimer Disease & Associated Disorders: October-November-December 2004 - Volume 18 - Issue 4 - p 185-189 Buy Abstract Optimism regarding the treatment and prevention of Alzheimer disease has begun to replace the attitude of therapeutic nihilism that clouded the field for so many decades. Neurotransmitter-based therapy with AChEls and NMDA receptor antagonists are now in current use; anti-inflammatory and anti-oxidative approaches as well as compounds to block Aβ aggregation are being tested in the clinic; β- and γ-secretase inhibitors designed to reduce generation of Aβ peptides are under development. One of the more provocative developments in this field was the idea of vaccination against β-amyloid. Despite vivid antagonism that was rapidly voiced by many concerned experts, there are actually several excellent reasons why brain β-amyloid plaques are attractive immunotherapeutic targets for the treatment and prevention of AD. © 2004 Lippincott Williams & Wilkins, Inc.